Replace Or Repair? Cardiologist, TriCares CEO On Changes In Tricuspid Valve Intervention

Replace Or Repair? Cardiologist, TriCares CEO On Changes In Tricuspid Valve Intervention

 

Tricuspid valve innovation has taken off since the US FDA’s 2023 authorizations of Edwards' Evoque and Abbott's TriClip systems. Whether to repair or replace tricuspid valves remains an open, nuanced question among cardiologists. Dr. Henrik Treede of University Hospital Mainz and TriCares CEO Ahmed Elmouelhi offer views on the evolving space.

Some Perspectives From Medtech Industry Leaders Heard At Octane OC

Some Perspectives From Medtech Industry Leaders Heard At Octane OC

 
• By 

The Octane Medical Innovation Forum brought together industry experts, entrepreneurs and investors to discuss a range of topics. Medtech Insight was on the ground to bring some memorable perspectives from industry leaders.

News We’re Watching: New FDA Approvals For Breast Implant, Colon Cancer Test, Imaging Agent; TAP Expansion, AI Standards

News We’re Watching: New FDA Approvals For Breast Implant, Colon Cancer Test, Imaging Agent; TAP Expansion, AI Standards

This week, Establishment Labs Holdings announced the FDA gave it premarket approval for Motiva breast implant, Cologuard lands FDA approval for Cologuard Plus and GE HealthCare gets FDA nod for a new imaging agent. The FDA announces another expansion for TAP into ophthalmology and radiology. The AAMI and CTA will join forces to develop standards for AI and ML-enabled health care products.  

Inbrain Has Sights On Parkinson’s Following First-In-Human Test Of Graphene-Based Implant

Inbrain Has Sights On Parkinson’s Following First-In-Human Test Of Graphene-Based Implant

 
• By 

Spain-based Inbrain Neuroelectronics plans first-in-human study to show safety of its graphene-based technology in direct contact with human brain while also developing a second interface for treating Parkinson’s disease.


Synchron Announces Positive Results From Stentrode BCI Study, Plans For Pivotal Study

Synchron Announces Positive Results From Stentrode BCI Study, Plans For Pivotal Study

 
• By 

After announcing positive results showing that its Stentrode BCI is safe in six patients, brain-computer interface company Synchron is planning a pivotal trial to eventually file for FDA approval.

J&J MedTech Keeps Up Cardiovascular Momentum With Shockwave E8 Launch In US

J&J MedTech Keeps Up Cardiovascular Momentum With Shockwave E8 Launch In US

 

Tim Schmid, executive VP and worldwide chairman of J&J MedTech, expects Shockwave, acquired in April, and Abiomed, purchased in late 2022, to be “long-term gems” for the company. Cardiovascular is among higher-growth segments where J&J has concentrated investments in recent years, along with robotic surgical systems.

Angiodynamics Initiates Thrombectomy Trial In Europe After Showing Positive Trial Results in US

Angiodynamics Initiates Thrombectomy Trial In Europe After Showing Positive Trial Results in US

 
• By 

According to Zacks Equity Research, the new trial seeks to support AlphaVac’s adoption in the European market, where pulmonary embolism prevalence and severity is an estimated 435,000 events annually.

‘You Can Get Paid’: Medtronic CEO On Monetizing AI

‘You Can Get Paid’: Medtronic CEO On Monetizing AI

 
• By 

Medtronic chairman and CEO Geoff Martha addressed the promise of artificial intelligence in the company’s medical technologies, AI monetization opportunities, and risk of AI overregulation in a 4 September session at the Wells Fargo Healthcare Conference.


LSX Medtech Panelists Talk AI, Market Access Strategies, Digital Therapeutics Reimbursement

LSX Medtech Panelists Talk AI, Market Access Strategies, Digital Therapeutics Reimbursement

 
• By 

Highlights from Medtech Insight's on-the-ground coverage of LSX in Boston. 

‘Catastrophic’ Risk Linked To Smiths Medical Trach Tubes

‘Catastrophic’ Risk Linked To Smiths Medical Trach Tubes

 

Smiths Medical has recalled scores of Bivona tracheostomy tubes due to a manufacturing defect that can result in disastrous consequences. The company reports multiple injuries, and one death, linked to the devices.

FDA Releases Six More De Novo Summaries

FDA Releases Six More De Novo Summaries

 
• By 

The US FDA released six more device classifications in early September, including products from Edwards, Interscope, and Baxter Healthcare.

News We’re Watching: $1B Judgement Against J&J Recalls For Abbott, Baxter, More; Karl Storz Announces Fujifilm Partnership

News We’re Watching: $1B Judgement Against J&J Recalls For Abbott, Baxter, More; Karl Storz Announces Fujifilm Partnership

 

This week, a Delaware court awarded Auris Health shareholders $1bn in a lawsuit against Johnson & Johnson; Abbott recalled some FreeStyle Libre 3 sensors; and McKesson purchased a controlling interest in a Florida cancer care chain.


Warning Letters – August 2024

Warning Letters – August 2024

The US Food and Drug Administration released six warning letters and two close-outs last month, including four warnings to marketers of unauthorized continuous positive airway pressure (CPAP) cleaners or sanitizers.

Digital Health Roundup: Digital Therapeutics Navigate GLP-1, Immersive Gaming; DHCoE AI Framework; Hello Heart

Digital Health Roundup: Digital Therapeutics Navigate GLP-1, Immersive Gaming; DHCoE AI Framework; Hello Heart

In this week’s Digital Health Roundup, Medtech Insight’s Ryan Nelson highlights Click Therapeutics’ FDA-cleared digital therapeutics (DTx) for depression and Sinaptica Therapeutics’ personalized neuromodulation for Alzheimer’s patients. Marion Webb discusses her interview with MindMaze’s John Krakauer on their gaming-focused DTx to help people recover from serious brain injuries. Elizabeth Orr introduces new voting members of the new Digital Health Advisory Committee and Natasha Barrow discusses Hello Heart’s new symptom-tracking feature in their heart-focused app.

Renata Medical Headed To Market With Stent For Children With Congenital Heart Defects

Renata Medical Headed To Market With Stent For Children With Congenital Heart Defects

 
• By 

Renata Medical has received US FDA clearance for its Minima Growth stent, which is designed for neonates, infants and young children and built to expand as the patient ages.

Six Deaths Linked To Inari Clot Removal Device

Six Deaths Linked To Inari Clot Removal Device

 

Inari Medical is updating use instructions for a clot-removing catheter due to the potential for serious adverse effects, including death.


News We’re Watching: AMP Sues FDA To Block Lab-Developed Test Rule; FDA Guidances; ICU Medical Infusion Pump Correction

News We’re Watching: AMP Sues FDA To Block Lab-Developed Test Rule; FDA Guidances; ICU Medical Infusion Pump Correction

This week, a medical group sued the FDA to block a lab-developed test rule; the FDA published guidance on device classifications; Defibtec issued a recall of its chest compression device and ICU Medical updated instructions for its infusion pump batteries; Maui Imaging raised a $4m DOD grant to put imaging tech into military-based trauma units.

Getinge To Acquire Paragonix Technologies For About $477M

Getinge To Acquire Paragonix Technologies For About $477M

 

Getinge says it plans to pay about $477m for organ transport and services company Paragonix Technologies in an effort to “redefine the market standard in transplantation.”

J&J Acquires Heart Failure Implant Company V-Wave For Up To $1.7Bn, Expanding Its Medtech Portfolio In Cardiology

J&J Acquires Heart Failure Implant Company V-Wave For Up To $1.7Bn, Expanding Its Medtech Portfolio In Cardiology

 
• By 

J&J buys heart failure implant company V-Wave, whose Ventura Interatrial Shunt could be the first device of its kind aimed to reach the roughly 800,000 patients in the US who experience heart failure and reduce ejection fraction every year.

Neptune Medical Leans Into GI Robotics, Spins Out Jupiter Endovascular

Neptune Medical Leans Into GI Robotics, Spins Out Jupiter Endovascular

 

Announced in conjunction with a $97m Series D financing round, Neptune underscores its gastrointestinal focus and robotics aspirations by spinning out Jupiter Endovascular, which will leverage $21m of the funding to support ongoing development of its Endoportal Control technology.